<生产厂家价格>

曲普瑞林

曲普瑞林用途

Triptorelin是一个GnRH兴奋剂,能够抑制雌二醇引起的细胞增殖。

曲普瑞林作用

曲普瑞林名称

[ CAS 号 ]:
57773-63-4

[ 中文名 ]:
曲普瑞林

[ 英文名 ]:
[D-Trp6]-LH-RH

[中文别名 ]:

普瑞林

[英文别名 ]:

triptorelinum
triptorelinum [INN_la]
triptoreline
TRIPORELIN
MFCD00167541
triptorelina
TRIPTORELIN AMIDE
UNII:9081Y98W2V
Triptorelin
TRIPTORELIN PAMOATE

曲普瑞林生物活性

[ 描述 ]:

Triptorelin是一个GnRH兴奋剂,能够抑制雌二醇引起的细胞增殖。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> GNRH受体

研究领域 >> 癌症

多肽产品

[参考文献]

[1]. Wei S et al. Triptorelin and cetrorelix induce immune responses and affect uterine development and expressions of genes and proteins of ESR1, LHR, and FSHR of mice. Immunopharmacol Immunotoxicol. 2016 Jun;38(3):197-204.

[相关活性小分子]

曲普瑞林物理化学性质

[ 密度 ]:
1.5±0.1 g/cm3

[ 分子式 ]:
C₆₄H₈₂N₁₈O₁₃

[ 分子量 ]:
1311.449

[ 精确质量 ]:
1310.630859

[ PSA ]:
487.92000

[ LogP ]:
-0.41

[ 外观性状 ]:
粉末

[ 折射率 ]:
1.723

[ 储存条件 ]:
−20°C

曲普瑞林安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H360

[ 警示性声明 ]:
P201-P308 + P313

[ 个人防护装备 ]:
Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T: Toxic;

[ 风险声明 (欧洲) ]:
R60

[ 安全声明 (欧洲) ]:
53-22-36/37/39-45

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

曲普瑞林文献

Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies.

Arch. Gynecol. Obstet. 287(3) , 447-53, (2013)

To evaluate the changes in the volume of rectovaginal endometriotic nodules infiltrating the rectum during 12-month treatment with hormonal therapies.This prospective, non-randomized, self-controlled ...

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.

J. Clin. Oncol. 31(7) , 903-9, (2013)

To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting o...

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

N. Engl. J. Med. 371(2) , 107-18, (2014)

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assi...

更多文献